Onassis Holdings Corp. announced its entry into the rejuvenation therapy market with a epigenetic programming technology. Through an exclusive perpetual license agreement with a leading Israeli university, Onassis Holdings will have the right to develop, manufacture, market, distribute, and sell products utilizing this cutting-edge technology worldwide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0312 USD | +0.52% | +0.65% | -12.85% |
2023 | Onassis Holdings Corp. announced that it expects to receive $75 million in funding | CI |
2023 | Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming | CI |
1st Jan change | Capi. | |
---|---|---|
-12.85% | 3.99M | |
+39.33% | 6.11B | |
-18.38% | 4.35B | |
-9.17% | 3.19B | |
+3.98% | 3.15B | |
-3.41% | 2.51B | |
+48.74% | 1.98B | |
-4.82% | 1.74B | |
-1.24% | 1.63B | |
-8.96% | 1.6B |
- Stock Market
- Equities
- ONSS Stock
- News Onassis Holdings Corp.
- Onassis Holdings Enters the Rejuvenation Therapy Race with Innovative Epigenetic Programming